Adrenal insufficiency

Adrenal insufficiency is an endocrine syndrome characterized by cortisol deficiency caused by reduced adrenal production or inadequate stimulation of the hypothalamic-pituitary-adrenal axis. From a physiological perspective, cortisol is the body’s protective hormone, allowing it to maintain hemodynamic stability, control energy metabolism, regulate the inflammatory response and adapt to stress. When this signal is lost, the body may compensate partially under basal conditions but becomes vulnerable to common events such as infections, dehydration, surgery, trauma or inappropriate withdrawal of glucocorticoids, with a risk of adrenal crisis.

In clinical practice, it is essential to distinguish three major categories. In primary adrenal insufficiency, the disorder affects the adrenal gland and the deficiency may involve both cortisol production and, often, aldosterone production, resulting in sodium loss, hypovolemia and hyperkalemia. In secondary and tertiary adrenal insufficiency, the disorder is central, involving the pituitary gland or hypothalamus respectively, and aldosterone is generally preserved because it is regulated mainly by the renin-angiotensin system. Hyponatremia due to relative vasopressin excess and susceptibility to hypoglycemia are more prominent. A further condition, now very common, is glucocorticoid-induced adrenal insufficiency, in which suppression of the axis by prolonged steroid treatment prevents the patient from increasing cortisol production when required.

The epidemiology of adrenal insufficiency varies considerably because it reflects causes with very different frequencies. Some are rare but associated with a high clinical risk, while others are common because of the widespread use of glucocorticoids. Chronic primary forms are uncommon in the general population and, in high-income countries, autoimmune adrenal disease is the predominant cause. Prevalence reported in European and North American studies is in the range of tens to a few hundred cases per million people, with distribution influenced by diagnostic methods, access to care and recognition of early or incomplete forms. Onset may occur at any age but is often observed in adulthood, with a higher proportion of women in autoimmune forms, consistently with the general epidemiology of autoimmune endocrine disorders.

Alongside isolated autoimmune disease, a substantial proportion of primary adrenal insufficiency occurs within autoimmune polyglandular syndromes. In these patients, the pre-test probability increases when autoimmune thyroiditis, type 1 diabetes, primary ovarian insufficiency, pernicious anemia, celiac disease or vitiligo coexist, because the immune system tends to affect multiple endocrine compartments over time. In clinical practice, diagnosis of the first component of the syndrome should prompt targeted surveillance for the others, because the development of adrenal insufficiency substantially changes the safety of numerous treatments and the management of intercurrent events.

Secondary and tertiary forms are uncommon when considered exclusively as consequences of pituitary or hypothalamic disorders, but they become epidemiologically relevant when iatrogenic and pharmacological causes are included. Pituitary tumors, sellar surgery and radiotherapy, pituitary apoplexy and infiltrative disorders may cause ACTH deficiency within a broader picture of hypopituitarism. Modern oncology has also increased the frequency of central dysfunctions associated with immunotherapy, particularly hypophysitis and corticotropic deficiency, which may emerge insidiously or present acutely with hypotension, severe fatigue and hyponatremia.

A central issue in terms of absolute numbers is glucocorticoid-induced adrenal insufficiency. Systemic steroid treatment is widely used in rheumatology, pulmonology, gastroenterology and general medicine. High-dose inhaled formulations, repeated injections, potent topical steroids applied to large areas and pharmacological combinations that increase systemic exposure may also contribute to axis suppression. Risk increases with cumulative dose, duration, potency, evening administration and patient frailty, but remains highly variable between individuals. Clinical epidemiology therefore depends strongly on prescribing practices and the quality of deprescribing and monitoring pathways.

Infectious and infiltrative factors also remain relevant in selected settings. Adrenal tuberculosis is now less common in industrialized countries than in the past, but remains an important cause of primary insufficiency in areas with a high prevalence of tuberculosis or in vulnerable populations, and may become apparent even long after treatment of the infection. Bilateral metastases, adrenal hemorrhage, severe sepsis, treatment with agents that interfere with steroidogenesis and genetic forms represent additional epidemiological groups. Although less common, they are clinically important because they are often associated with acute presentations or specific therapeutic requirements.

Finally, the likelihood of adverse outcomes depends not only on the cause but also on the ability to recognize the condition early and prevent crisis. Advanced age, cardiovascular and renal comorbidities, social or care-related difficulties, limited access to health education and diagnostic delays increase the clinical burden. In this context, the real epidemiology of adrenal insufficiency also includes patients who remain undiagnosed or are diagnosed late, with the condition being identified only during an intercurrent event that reveals their inability to sustain an adequate stress response.

Adrenal insufficiency can be understood as the loss of an endocrine signal that is central to homeostasis, with consequences emerging gradually or suddenly depending on the speed of the damage and the presence of stress. Under normal conditions, the hypothalamus secretes CRH and vasopressin in response to circadian signals and stress. The pituitary gland releases ACTH, which stimulates the zona fasciculata of the adrenal cortex to produce cortisol. Cortisol exerts negative feedback on the hypothalamus and pituitary gland and finely regulates metabolism, immunity and cardiovascular function. Loss of function at any of these levels may cause cortisol deficiency, but the pathophysiology differs substantially between primary and central forms.

In primary adrenal insufficiency, the underlying disorder is destruction or dysfunction of adrenal tissue. The most common cause in developed countries is autoimmune adrenalitis, mediated by T lymphocytes and frequently associated with autoantibodies against steroidogenic enzymes, particularly 21-hydroxylase. Progressive damage reduces cortisol synthesis and, when the zona glomerulosa is involved, also reduces aldosterone production. The body responds with a marked increase in ACTH because of loss of feedback, and the excess of pro-opiomelanocortin-derived peptides accounts for the typical cutaneous and mucosal hyperpigmentation of the primary form. In advanced cases, mineralocorticoid loss causes renal sodium wasting, contraction of extracellular volume, hypotension and renin activation, with a tendency toward hyperkalemia and mild metabolic acidosis. This creates a fragile physiological state in which any stress may precipitate circulatory collapse.

Among non-autoimmune primary causes, infections, particularly tuberculosis in selected settings, infiltrative disorders such as bilateral metastases and lymphomas, adrenal hemorrhage and some genetic or iatrogenic forms share a common mechanism: a critical reduction in functioning steroidogenic tissue. In bilateral hemorrhage, which is often associated with severe sepsis, coagulation disorders or anticoagulant treatment, sudden loss of function may cause an acute presentation dominated by shock and hypoglycemia, in which treatment must precede diagnostic confirmation. In other cases, the damage is insidious and progressive, with nonspecific symptoms reflecting months or years of insufficient cortisol production and a gradually declining ability to maintain blood pressure, appetite and energy levels.

In secondary and tertiary adrenal insufficiency, pathogenesis is different because the adrenal gland is potentially intact but does not receive adequate stimulation from ACTH. ACTH deficiency reduces cortisol synthesis and causes atrophy of the zona fasciculata over time, while aldosterone production is usually preserved. Consequently, hypotension and hypovolemia may be less pronounced than in the primary form, hyperkalemia is generally absent and hyperpigmentation does not occur because ACTH is low or inappropriately normal. The biochemical phenotype is instead more likely to include hyponatremia due to a relative increase in vasopressin and impaired free-water clearance, together with susceptibility to hypoglycemia, particularly in children, older adults, patients with reduced hepatic reserve or during prolonged fasting.

Glucocorticoid-induced adrenal insufficiency represents a pathophysiological model of iatrogenic negative feedback. Chronic exposure to glucocorticoids suppresses CRH and ACTH, reduces adrenal stimulation and leads to decreased axis responsiveness. During treatment, the patient may remain asymptomatic because glucocorticoids replace cortisol, but if the dose is reduced too rapidly or withdrawn, the axis cannot resume endogenous production within the required timeframe. The risk is not limited to withdrawal symptoms but primarily concerns the inability to increase cortisol during infections or surgery. For this reason, its pathophysiology is closely linked to stress dosing and tapering strategies.

At the systemic level, cortisol deficiency reduces vascular responsiveness to catecholamines and angiotensin II, impairs the maintenance of vascular tone and cardiac output during stress and alters the inflammatory response, with a risk of an inappropriate reaction to infection. Metabolically, cortisol is necessary to sustain gluconeogenesis and substrate availability. Its deficiency promotes hypoglycemia, fatigue, weight loss and reduced appetite. Gastrointestinal symptoms such as nausea, abdominal pain and vomiting result from the interaction between hypoperfusion, electrolyte abnormalities and vulnerability to stress. The combination of these mechanisms explains why adrenal insufficiency may present either as a nonspecific multisystem disorder or as a sudden and potentially fatal emergency.

The clinical presentation of adrenal insufficiency is often insidious because the initial symptoms are common to many internal medicine disorders. The common denominator is a progressive loss of energy with a reduced ability to tolerate physical and psychological stress, eventually reaching a point at which minor events cause marked functional deterioration. The speed of onset, the presence or absence of mineralocorticoid deficiency and the etiological context determine different clinical phenotypes, but the logic of the clinical assessment remains the same: reconstruct the time course of symptoms and identify discriminating signs that point toward cortisol deficiency.

During the medical history, patients with chronic disease often report persistent fatigue disproportionate to exertion, reduced physical performance, daytime sleepiness, loss of appetite and weight loss. Gastrointestinal symptoms such as nausea, early satiety, vague abdominal pain and unstable bowel habits are common and may dominate the clinical picture. Orthostatic dizziness, syncope, reduced heat tolerance and craving for salty foods are particularly suggestive of primary forms associated with sodium loss. A history of recurrent episodes of malaise following viral infections, with a slow and disproportionate recovery, is a useful clinical clue because it reflects an inability to increase cortisol appropriately in response to stress.

In the primary form, hyperpigmentation is an important clinical sign. It may be evident in palmar creases, scars, gums and sun-exposed areas, but it may also be subtle and detectable only through a systematic examination. The association with vitiligo or other autoimmune features further supports the suspicion. Symptoms of aldosterone deficiency, when present, include marked orthostatic hypotension, muscle cramps, relative polyuria and deterioration during dehydration. In central forms, by contrast, the skin may appear pale, hyperpigmentation is absent and signs of hypopituitarism may coexist, including reduced libido, menstrual irregularities, cold intolerance or headache, depending on the underlying disorder.

The physical examination should systematically assess hydration status, supine and standing blood pressure, heart rate, body weight, muscle mass and cutaneous or mucosal signs. Hypotension, particularly orthostatic hypotension, is common and, in primary forms, may be associated with compensatory tachycardia, dry skin and signs of volume depletion. Proximal weakness and reduced muscle mass may reflect both undernutrition and impaired energy availability. Low-grade fever or hypothermia are not specific, but in a frail patient they may indicate an intercurrent event that is pushing the axis beyond its residual capacity. In the presence of vomiting, confusion or reduced alertness, acute decompensation of the axis should be considered early.

A particularly important clinical feature is variability during stress. Patients with partially compensated adrenal insufficiency may appear relatively stable under basal conditions but rapidly develop hypotension, loss of appetite, persistent nausea, abdominal pain and severe weakness during influenza or gastroenteritis. This stress-sensitive pattern is a strong clinical indicator, particularly in patients with a history of prolonged steroid treatment, in whom axis suppression may remain unrecognized until the first significant intercurrent event.

In acute cases, the syndrome may present with a clinical picture indistinguishable from septic shock or an acute abdomen, including vomiting, diarrhea, abdominal pain, fever, refractory hypotension, hypoglycemia and electrolyte abnormalities. The presence of marked hyponatremia, hyperkalemia and hypoglycemia in the setting of hypotension should immediately suggest cortisol deficiency and, in primary forms, concomitant mineralocorticoid deficiency. In this situation, immediate treatment is the clinical priority because diagnostic delay directly increases mortality.

Adrenal insufficiency should be suspected when nonspecific symptoms become physiologically consistent with cortisol deficiency, particularly when associated with signs of hemodynamic instability or electrolyte abnormalities. Persistent fatigue, weight loss and recurrent nausea are common to many disorders, but become highly suggestive when accompanied by orthostatic hypotension, hyponatremia, hypoglycemia or hyperpigmentation. In internal medicine, the combination of chronic symptoms and dramatic deterioration during mild infections is one of the most useful patterns for early recognition of the condition.

Unexplained hypotension, particularly when refractory to fluids or vasopressors in acute settings, is a warning sign. In the emergency department and critical care setting, every patient with shock and hyponatremia, hypoglycemia or hyperkalemia should also be assessed for adrenal insufficiency, especially in the presence of a history of glucocorticoid treatment, recent steroid withdrawal, sepsis, anticoagulant treatment or autoimmune disease. In such settings, hydrocortisone treatment should not be delayed while awaiting laboratory confirmation when clinical suspicion is reasonable.

Suspicion should be particularly high in the presence of known predisposing factors. In patients with other autoimmune endocrine disorders or cutaneous signs consistent with autoimmunity, hyponatremia or marked fatigue carries a different diagnostic weight than in the general population. In patients with known pituitary disorders, sellar surgery or radiotherapy, the development of fatigue, hyponatremia or hypoglycemia, particularly during intercurrent illness, suggests ACTH deficiency even when other pituitary deficiencies are already being treated.

A very common clinical setting is steroid treatment. Any patient who has taken systemic glucocorticoids for weeks or months, or who has received repeated injections or high-dose inhaled formulations, may develop axis suppression. Suspicion should arise when weakness, nausea, hypotension, myalgia and generalized malaise develop during dose reduction or after withdrawal, particularly when these symptoms are disproportionate to inflammatory markers or evidence of infection. In such cases, adrenal insufficiency may be mistaken for a recurrence of the underlying disease or an anxiety-depressive syndrome, leading to diagnostic delay.

Finally, some situations should be regarded as sentinel events. Recurrent hyponatremia without an evident cause, hypoglycemic episodes in people without diabetes, episodes of orthostatic syncope, recurrent abdominal pain with inconclusive inflammatory markers and a reduced blood pressure response to catecholamines are settings in which suspicion should be explicit. Once the possibility has been recognized, the next step should be a timely and orderly diagnostic pathway, because confirmation and etiological definition guide replacement strategies and, above all, crisis prevention.

The diagnosis of adrenal insufficiency requires a rational pathway integrating biochemical confirmation of cortisol deficiency with identification of the level of the defect, distinguishing primary forms from central forms and iatrogenic suppression. When the clinical condition permits, the first step is measurement of morning plasma cortisol, ideally during the early hours of the day, together with ACTH and a safety panel including sodium, potassium, blood glucose and markers of renal function. Clearly low values in a symptomatic patient strengthen the suspicion, but interpretation must take biological variability, acute stress and pharmacological interference into account.

In most cases, diagnostic confirmation requires a dynamic test assessing the ability of the adrenal gland to produce cortisol in response to stimulation. The most widely used procedure is stimulation with synthetic ACTH, which measures the cortisol response to a standardized stimulus. The clinical purpose is to distinguish an adrenal gland that is capable of responding, as may occur in some recent or partial central forms, from one that is unresponsive because of primary destruction or atrophy due to chronic ACTH deficiency. In acute conditions or when adrenal crisis is strongly suspected, cortisol and ACTH samples should be obtained before treatment when possible, but hydrocortisone and fluid administration must not be delayed.

Diagnostic assessment of adrenal insufficiency

• Confirmation of cortisol deficiency through morning measurement and, when indicated, a dynamic stimulation test documenting an inadequate secretory response.
• Identification of the level of the defect using baseline ACTH and the electrolyte profile: elevated ACTH with hyponatremia and possible hyperkalemia suggests a primary form, while low or inappropriately normal ACTH suggests a central form or iatrogenic suppression.
• Investigation of the cause and comorbidities: 21-hydroxylase antibodies and assessment of the renin-aldosterone system in primary forms, targeted adrenal or pituitary imaging when suggested by the clinical context, and careful review of exposure to glucocorticoids and interfering agents.
• Assessment of the risk of crisis and complications using electrocardiography, blood glucose, volume status and infection markers in acute presentations or frail patients, initiating treatment and prevention measures during the diagnostic process.

The distinction between primary and central insufficiency is not merely academic because it changes treatment. In the primary form, it is essential to evaluate the mineralocorticoid component using plasma renin activity or direct renin, aldosterone and potassium, because replacement with fludrocortisone may be required for hemodynamic stability and electrolyte control. Identification of autoimmune adrenal disease also supports screening for other autoimmune endocrine disorders and counseling regarding their possible development over time. In the central form, attention shifts to the overall pituitary picture, including assessment of other hormonal axes and sellar imaging when indicated, because ACTH deficiency may be part of complex hypopituitarism requiring the correct treatment sequence.

In patients with glucocorticoid-induced insufficiency, the pharmacological history is an integral part of diagnosis. Duration, dose, formulation, timing of administration and withdrawal method must be reconstructed, including inhaled treatment, potent topical steroids applied to large areas and repeated injections. Assessment of axis recovery may require dynamic testing at appropriate stages of tapering, because a single cortisol value may not adequately reflect the ability to respond to stress. In this setting, the main diagnostic objectives are to establish the safety of dose reduction, the need for stress coverage and appropriate follow-up criteria.

Once the biochemical diagnosis has been established, complete etiological definition requires a selective approach. In non-autoimmune primary forms, adrenal imaging may identify infiltration, hemorrhage, calcification or bilateral masses. In infectious and oncological settings, diagnosis must be integrated into the systemic assessment. In central forms, pituitary magnetic resonance imaging and assessment of the other hormonal axes guide treatment and prognosis. In every case, the diagnostic pathway should be designed to avoid two opposite clinical errors: delaying life-saving treatment in an acute presentation or incorrectly attributing nonspecific symptoms to adrenal insufficiency without solid and reproducible confirmation.

Classification of adrenal insufficiency should link the site of the defect to its therapeutic implications and risk of crisis. The main distinction is between primary, secondary and tertiary adrenal insufficiency. In the primary form, the adrenal gland is unable to produce cortisol and often aldosterone, with elevated ACTH and clinical signs such as hyperpigmentation and salt craving. In the secondary form, ACTH deficiency is caused by pituitary disease and aldosterone is generally preserved, while in the tertiary form reduced stimulation is hypothalamic or functional, including glucocorticoid-induced suppression. The phenotype resembles that of secondary insufficiency but is often linked to the treatment history. This classification is not static because prolonged suppression may cause adrenal atrophy and slow recovery, creating diagnostic gray areas in which the response to dynamic testing depends on the duration of the deficiency and the timing of the test.

A second classification concerns the completeness of the deficiency. Complete forms are characterized by a clear inability to produce cortisol even during stimulation, while partial or early forms may show borderline basal cortisol values and an inadequate response to stress despite not being completely absent. These forms are clinically relevant because they may become apparent only under stress and are particularly common in patients tapering steroid treatment or with recent pituitary disease. Severity therefore does not always correspond to the intensity of symptoms under basal conditions, but rather to the ability to sustain a predictable stress.

From a clinical perspective, it is useful to distinguish stable chronic forms receiving replacement treatment, chronic forms that remain undiagnosed or inadequately treated, and acute or decompensated forms. Adrenal crisis represents the extreme of severity and is characterized by hemodynamic collapse, dehydration, electrolyte abnormalities and often severe gastrointestinal symptoms. However, an intermediate stage of acute deterioration may occur before overt crisis, in which nausea, vomiting and weakness prevent oral treatment. This already represents an indication for parenteral treatment and urgent assessment. The ability to recognize this intermediate stage is one of the main determinants of crisis prevention.

A further etiological classification, relevant to prognosis and follow-up, includes autoimmune adrenalitis, infections and infiltrative disorders, hemorrhage, metastases, agents that interfere with steroidogenesis, pituitary disorders and glucocorticoid-induced suppression. The same site of dysfunction may have different implications. Primary autoimmune insufficiency is associated with a risk of other endocrine disorders and requires surveillance for polyglandular autoimmunity, while primary insufficiency caused by metastases occurs within an oncological pathway in which acute management and crisis prevention during systemic treatment may take priority.

Finally, classification must incorporate the risk associated with specific settings such as pregnancy, surgery and acute illness. In these situations, even apparently well-compensated patients may decompensate if they do not implement an appropriate dose increase during stress or lack access to parenteral treatment. Clinical severity is therefore a dynamic concept determined by the interaction between endocrine reserve, stress burden, recognition of symptoms and organization of the emergency pathway.

Treatment of adrenal insufficiency is based on two inseparable objectives: replacing cortisol in a physiologically plausible manner under basal conditions and ensuring an adequate response to stress to prevent adrenal crisis. Treatment must be individualized according to the site of the defect, the presence of mineralocorticoid deficiency, the patient’s clinical profile and specific risk settings. The most dangerous error is not only chronic under-replacement, but also failure to increase glucocorticoid coverage rapidly when required. The modern strategy therefore regards replacement treatment as an educational and organizational pathway as well as a pharmacological intervention.

In most patients, basal cortisol replacement is provided with hydrocortisone in divided doses, with a larger dose in the morning and smaller doses later in the day to reproduce circadian physiology as closely as possible. Alternatives include low-dose prednisolone in selected regimens, with care to avoid excessive glucocorticoid exposure. Dose titration cannot be based on a single laboratory marker because there is no cortisol equivalent of thyroid-stimulating hormone. It is instead guided by clinical parameters such as energy, body weight, blood pressure, exercise tolerance, sleep quality and the absence of signs of either excess or deficiency. The aim is to reduce symptoms and crisis risk without causing complications of overtreatment, including weight gain, hypertension, osteopenia and metabolic abnormalities.

In primary insufficiency associated with mineralocorticoid deficiency, replacement with fludrocortisone is also required. The dose is adjusted according to blood pressure, orthostatic symptoms, potassium and indicators of renin-angiotensin system activity. Education regarding salt intake and temporary adjustments during intense heat, diarrhea or profuse sweating is an integral component of treatment. The mineralocorticoid component is often crucial for hemodynamic stability and prevention of refractory hypotension, particularly during periods of dehydration.

A fundamental element is stress dosing. During fever, infection, trauma or medical procedures, the glucocorticoid dose must be increased according to clear, previously agreed rules. If vomiting or diarrhea prevents oral treatment, parenteral hydrocortisone and urgent clinical assessment are required. Crisis prevention requires the patient to have access to an injection kit and emergency documentation, and for caregivers and healthcare professionals to recognize and treat deterioration promptly.

In central forms, mineralocorticoid treatment is usually unnecessary and management focuses on cortisol replacement and treatment of the underlying pituitary disorder. In hypopituitarism, the order in which hormonal deficiencies are corrected is clinically important because initiation of thyroid treatment in a patient with untreated cortisol deficiency may precipitate decompensation. Assessment of the corticotropic axis therefore takes priority when correction of other deficiencies is being planned. In immunotherapy-related hypophysitis or following pituitary surgery, treatment should be adapted to the possibility of recovery over time, with planned reassessment and safe dose reduction strategies when appropriate.

In glucocorticoid-induced adrenal insufficiency, treatment includes gradual dose reduction and monitoring of the axis, with the aim of restoring endogenous function without exposing the patient to risk during stress. Management requires a balance between control of the underlying disorder and endocrine safety. Some patients need to remain on a coverage dose for prolonged periods and require clear rules for dose escalation during intercurrent illness. Collaboration between the specialist prescribing steroids and the clinician managing the axis is essential to prevent inappropriate withdrawal or excessively rapid reduction.

Finally, in selected patients with primary insufficiency, modified-release hydrocortisone formulations may be considered to improve the circadian profile, with potential benefits for quality of life, metabolism and susceptibility to infections in specific settings. These options do not replace crisis-prevention rules or eliminate the need for education and organization, but represent a therapeutic development aimed at reducing the impact of chronically nonphysiological replacement.

Follow-up of adrenal insufficiency has several objectives: maintaining adequate replacement without overtreatment, preventing and recognizing crisis early, managing comorbidities and adapting treatment to changes in the patient’s life. Because there is no single reliable biomarker for titrating glucocorticoid replacement, monitoring must be clinical and structured, with attention to blood pressure, body weight, symptoms, daily energy patterns and signs of excess such as weight gain, edema, hypertension and sleep disturbance. The quality of follow-up is reflected in fewer emergency visits, the patient’s ability to manage minor stresses and the prevention of acute events in predictable settings.

In patients with primary insufficiency, the mineralocorticoid component requires periodic monitoring of blood pressure, orthostatic symptoms, electrolytes and indicators of the renin-angiotensin system to adjust fludrocortisone. Insufficient replacement causes hypotension, fatigue, salt craving and relative hyperkalemia, while excessive replacement may promote hypertension, hypokalemia and edema. Follow-up should also include counseling on hydration, heat exposure, physical exercise and strategies to prevent dehydration because these factors directly affect hemodynamic stability.

A cornerstone of monitoring is continued education regarding dose escalation during intercurrent illness, dental procedures or invasive interventions, together with periodic verification that the patient possesses an emergency kit and documentation and knows how to use them. Reviewing practical scenarios is part of follow-up because many crises occur not because treatment has not been prescribed, but because of operational uncertainty during an acute episode. It is also essential for the patient to inform healthcare professionals during hospital admission or before procedures, because perioperative adjustment of glucocorticoids is critical to prevent hypotension and complications.

In patients with central insufficiency, follow-up should be integrated with management of the overall pituitary disorder. Changes in thyroid, gonadal or growth hormone replacement may alter glucocorticoid requirements, and the hormonal profile should be reassessed when new symptoms arise or other treatments are modified. Imaging and specialist monitoring depend on the underlying disorder, but the main clinical principles remain prevention of acute events and avoidance of chronic overtreatment that worsens the metabolic and skeletal profile.

In glucocorticoid-induced insufficiency, follow-up includes planning the taper, periodically assessing recovery of the axis and identifying patients who remain at risk during stress even when basal symptoms are minimal. In these cases, a written plan specifying when to increase the dose, when to switch to parenteral administration and when to contact the clinician is useful because operational uncertainty is one of the main factors that can turn a manageable condition into a crisis.

Finally, follow-up should include quality-of-life and long-term safety issues. Sleep disturbance, anxiety related to the risk of crisis, social limitations, occupational difficulties and management of physical activity may persist despite adequate treatment and may require educational interventions and, in some cases, modification of the treatment schedule. Effective monitoring is that which enables the patient to manage daily life independently, reduces the real-world impact of the disorder and maintains a low-risk profile in predictable situations.

The prognosis of adrenal insufficiency is generally favorable when diagnosis is made early, replacement treatment is appropriate and the patient is well educated regarding stress management. Nevertheless, the condition remains associated with a risk of adverse events, primarily because of the possibility of adrenal crisis and the long-term effects of glucocorticoid replacement that cannot perfectly reproduce physiology. Prognosis therefore depends not only on treatment itself but also on the quality of care pathways, access to emergency care, continuity of follow-up and prevention of management errors during infections, procedures and hospital admissions.

The most serious acute complication is adrenal crisis, characterized by hypotension, dehydration, electrolyte abnormalities and often severe gastrointestinal symptoms progressing to collapse. It is potentially fatal but can be prevented in most cases through education, availability of parenteral treatment and early recognition. Incomplete forms or acute deterioration that does not yet meet criteria for shock may still have a major clinical impact by causing repeated emergency visits, dehydration, loss of working days and impaired quality of life. Prevention depends on rapid escalation of glucocorticoid coverage and the ability to switch to parenteral administration when oral absorption is compromised.

Chronic complications may result from either under-replacement or over-replacement. Insufficient treatment is associated with persistent fatigue, reduced performance, hypotension and vulnerability to stress, with a risk of crisis. Excessive treatment, even if modest but prolonged, may promote weight gain, hypertension, diabetes, dyslipidemia and reduced bone mineral density, increasing the risk of fractures. Dose balance is therefore a dynamic process requiring repeated reassessment over time, particularly when body weight, age, concomitant treatment or lifestyle changes.

In primary insufficiency, specific complications include electrolyte instability caused by aldosterone deficiency and a risk of hyperkalemia, particularly during dehydration or when medications that increase potassium are also used. The autoimmune context also increases the risk of developing other endocrine disorders, which may influence prognosis and management. The onset of hypothyroidism, type 1 diabetes or other conditions requires treatment adjustment and an integrated approach. In central forms, risk is often linked to the underlying pituitary disorder and the coexistence of other hormonal deficiencies that may conceal or amplify symptoms and complications.

An important prognostic factor is adherence to preventive measures and training. Patients who have emergency resources, understand stress-dosing rules and have clear access pathways to care substantially reduce the risk of crisis and hospitalization. At the same time, treatment strategies that improve the circadian profile of glucocorticoid replacement may help reduce residual symptoms and metabolic complications in selected subgroups, although crisis prevention remains the primary objective.

Overall, adrenal insufficiency is a manageable condition compatible with a good quality of life, but it requires process-based medicine: accurate diagnosis, etiological distinction, individualized replacement treatment, structured education and continuous follow-up. When any of these elements is absent, the disorder may change from a controllable syndrome into a systemic risk factor, particularly during intercurrent events that reveal the loss of endocrine resilience.